Answers are grounded in this paper and cite their sources.
We performed a comprehensive analysis of ancestral associations with somatic mutations in a real-world pan-cancer cohort, including >5,000 non-European individuals. Using an FDA-authorized tumor sequencing panel and an FDA-recognized oncology knowledge base, we detected differences in the prevalence of clinically actionable alterations, potentially contributing to health care disparities affecting underrepresented populations. This article is highlighted in the In This Issue feature, p. 2483.
No takes yet. Share an insight, caveat, or question.
Arora et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: